Date: 2016-01-09
Type of information: Nomination
Compound:
Company: Y-mAbs Therapeutics (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 6, 2016, Y-mAbs Therapeutics announced an expansion of the management team. Dr. Torben Lund-Hansen, PhD, former site manager and SVP, Technical Operations for Genmab, has been appointed to SVP, Technical Operations to drive the development of the company’s manufacturing activities. Dr. Ole Baadsgaard, DMSc, former SVP, Medical Affairs for Genmab has been appointed to SVP, Chief Medical Officer to utilize his extensive international clinical and scientific experience in executing focused and prioritized antibody drug development for YmAbs.
Financial terms:
Latest news:
